Silence Therapeutics plc

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

SLN$19.75+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share data)

	Year ended December 31,
Note · 2025 · 2024
Current assets
Cash and cash equivalents	12		$11,277		$121,330
Short-term investments	12		73,837		26,004
R&D benefit receivable		22,007		24,396
Other current assets	13		11,537		14,664
Trade receivables	14		-		972
Total current assets		118,658		187,366
Property, plant and equipment, net	9		1,581		1,818
Operating lease right-of-use assets	16		167		157
Goodwill	10		10,621		9,392
Intangible assets	11		288		312
Other long-term assets	13		127		3,590
Total assets		$131,442		$202,635
Current liabilities
Contract liabilities	17		$(168)		$(306)
Trade and other payables	15		(13,356)		(16,399)
Operating lease liabilities, current	16		(89)		(117)
Total current liabilities		(13,613)		(16,822)
Contract liabilities	17		(55,454)		(51,790)
Operating lease liabilities, long-term	16		(71)		-
Total liabilities		$(69,138)		$(68,612)
Commitments and contingencies (Note 21)
Shareholders’ equity
Ordinary shares - par value £0.05 per share; 141,701,848 shares issued at December 31, 2025 (2024: 141,674,074)	19		(10,290)		(10,288)
Additional paid-in capital		(617,562)		(609,560)
Accumulated deficit		562,572		474,044
Accumulated other comprehensive loss		2,976		11,781
Total shareholders' equity		(62,304)		(134,023)
Total liabilities and shareholders' equity		$(131,442)		$(202,635)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.